Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies

Progressive Metastatic Malignancies Clinical Trial

Official title:

Phase I Study of ALT-801 in Patients With Progressive Metastatic Malignancies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00496860
• Other study ID #: CA-ALT-801-01-06
• Status: Completed
• Phase: Phase 1
• First received: July 3, 2007
• Last updated: July 17, 2013
• Start date: May 2007
• Est. completion date: October 2009

Study information

• Verified date: July 2013
• Source: Altor Bioscience Corporation
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1, open-labeled, non-randomized, multi-center, competitive enrollment and dose-escalation study of ALT-801, the study drug. The purpose of this study is to evaluate the safety, determine the maximum-tolerated dose (MTD) and characterize the pharmacokinetic profile of ALT-801 in previously treated patients with progressive metastatic malignancies. ALT-801, a recombinant fusion protein with a interleukin-2 (IL-2) component, has a targeting mechanism that recognizes tumor cells with a specific tumor marker.

Description:

Most current cancer treatment strategies involve the use of chemotherapeutic or biological drugs that exhibit variable efficacy and considerable toxicity. The limitations are often the result of the adverse side effects of the therapeutic drug on normal tissues. One approach to control these effects is to target the therapy to the tumor site. Of the identified tumor antigens, the human p53 tumor suppressor protein is overexpressed in a wide range of human malignancies. p53 is an intracellular tumor suppressor protein that acts to arrest the proliferation of cells. When mutated, it loses its ability to suppress abnormal proliferation and exhibits a longer half-life than the wild-type protein, allowing for its accumulation in tumors. In addition, p53 overexpression correlates with tumor transformation and aggression and is associated with lower overall survival rates and resistance to chemotherapeutic intervention in cancer patients. Therefore, p53 appears to be a marker for a considerable number of human malignancies and represents a good target for immunotherapeutics. However, p53 cannot be used as a target for antibodies because it is not displayed independently on the cell surface. Instead, the p53 protein is processed intracellularly into peptide fragments that are then displayed on the cell surface in the context of major histocompatibility complex (MHC). These peptide/MHC complexes are recognized by T-cells via their T-cell receptors (TCRs). Recently it has been confirmed that the peptide fragment is significantly elevated in a wide range of human tumor tissues, particularly in melanoma, renal, lung, breast, colorectal, bladder, ovary, stomach, esophagus, lymphoma, liver, leukemia, and head & neck cancer. Targeted approaches to concentrate therapeutic cytokines at the tumor sites that express p53 could provide considerable advantages over current treatment.

Interleukin-2 (IL-2) is a well-characterized growth factor for immune effector cells which play critical roles in tumor control and rejection. A recombinant human IL-2 has been approved for treating metastatic melanoma and renal cell carcinoma. However, the major drawback of IL-2 therapy is its severe systemic toxicity. As a result, use of high dose IL-2 is limited to specialized programs with experienced personnel and it is generally offered to patients who are responsive and have excellent organ function. Thus, there is a critical need for innovative strategies that enhance the effects of IL-2 or reduce its toxicity without compromising clinical benefits.

The study drug, ALT-801, is a biologic compound composed of interleukin-2 (IL-2) genetically fused to a humanized soluble T-cell receptor directed against the p53-derived antigen. This study is to evaluate whether directing IL-2 activity using ALT-801 to the patient's tumor sites that overexpress p53 results in clinical benefits.

The study drug will be administered by bolus intravenous infusion in an in-patient hospital setting under the supervision of a qualified physician experienced in the use of anti-cancer agents including high dose IL-2. An intensive care facility and specialists skilled in cardiopulmonary or intensive care medicine must be available. There are two treatment cycles. For each treatment cycle, patients will be admitted to the hospital, remain in the hospital during the study drug infusion period, and be discharged from the hospital the day after the last infusion at the Principal Investigator's discretion. There is a 10-day resting period between the treatment cycles. Tumor assessments will be done at weeks 7 and 11 after starting the study drug.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 26
• Est. completion date: October 2009
• Est. primary completion date: October 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

ENTRY CRITERIA:

DISEASE CHARACTERISTICS:

• Locally advanced or metastatic malignancies

• Histologically or cytologically confirmed

• Evaluable

• Surgically and medically incurable

• Not responding to standard therapy or no other standard therapy exists

• Human leukocyte antigen (HLA)-A2.1/p53 positive

PRIOR/CONCURRENT THERAPY:

• No prior Proleukin therapy within one year

• No concurrent radiotherapy, chemotherapy, or other immunotherapy

• More than 4 weeks since prior major radiotherapy

• More than 4 weeks since prior cytotoxic therapy

• More than 6 weeks since prior nitrosoureas therapy

• More than 8 weeks since prior monoclonal antibody therapy

PATIENT CHARACTERISTICS:

Life expectancy

• > 3 months

Performance status

• Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1

Bone marrow reserve

• Absolute neutrophil count (AGC/ANC) = 1,500/microliters (uL)

• Platelets =100,000/uL

• Hemoglobin = 10g/dL

Renal function

• Serum creatinine = 1.5 X Upper limit of normal (ULN)

Hepatic function

• Total bilirubin = 1.5 X ULN

• Aspartate Aminotransferase (AST) = 2.5 X ULN

• Alkaline phosphatase = 2.5 X ULN

• Prothrombin time (PT) or international normalized ratio (INR) = 1.5 X ULN

• Activated partial thromboplastin time (aPTT) = 1.5 X ULN

Cardiovascular

• May be safely tapered off anti-hypertensives if currently on anti-hypertensives

• New York Heart Association classification I or II

• No congestive heart failure <6 months

• No unstable angina pectoris <6 months

• No myocardial infarction <6 months

• No history of ventricular arrhythmias

• Normal cardiac stress test required if any of the following is present:

• Over age 50

• History of abnormal EKG

• Symptoms of cardiac ischemia or arrhythmia

Pulmonary

• Normal pulmonary function test (FEV1 = 75% of predicted value) if any of the following is present:

• Prolonged history of cigarette smoking

• Symptoms of respiratory dysfunction

Other

• No known autoimmune disease

• No known HIV positive

• No psychiatric illness/social situations that would limit study compliance

• No history or evidence of central nervous system (CNS) disease

• No active systemic infection requiring parental antibiotic therapy

• No systemic steroid therapy required

• No prior organ allograft

• Not receiving other investigational agents

• Not receiving chronic medication for asthma

• Not pregnant or nursing

• Fertile patients must use effective contraception

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Neoplasms
• Progressive Metastatic Malignancies

Intervention

Biological:
• ALT-801
Dose escalation (0.015 mg/kg, 0.04 mg/kg, 0.08 mg/kg, 0.12 mg/kg, 0.14 mg/kg, 0.16 mg/kg), intravenous infusions, two treatment cycle, each cycle with 4 daily on-dose infusion, 10 days rest between cycles.

Locations

Country	Name	City	State
United States	University of Colorado, Anschutz Cancer Pavillion	Aurora	Colorado
United States	MD Anderson Cancer Center Orlando	Orlando	Florida
United States	University of Washington, Seattle Cancer Care Center	Seattle	Washington
United States	H. Lee Moffitt Cancer Center & Research Institute	Tampa	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Altor Bioscience Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Safety and Toxicity of ALT-801 in Patients With Progressive Metastatic Malignancies	Number of serious adverse events per cohort	18 months	Yes
Primary	The Maximum-tolerated Dose (MTD) of ALT-801	Number of dose limiting toxicities (DLTs). A DLT is a toxicity that results in patient withdrawal from the study as defined in the protocol.	18 months	Yes
Secondary	Clinical Antitumor Response to ALT-801	Number of subjects with a complete response (CR), partial response (PR) or stable disease (SD). CR is defined as disappearance of all tumor lesions selected for measurement. PR is defined as at least 30% decrease in the sum of all tumor lesions selected for measurement. Stable disease is defined as neither sufficient tumor shrinkage to qualify for PR nor sufficient tumor increase to qualify for progressive disease (PD) which is defined as at least 20% increase the sum of the all tumor lesions selected for measurement.	24 months	No
Secondary	ALT-801 Induced Cell-mediated Immune Responses	Number of tumor-responsive (interferon-gamma positive (IFNg+)) immune cells in blood post dosing	24 months	No
Secondary	Immunogenicity of ALT-801	Titer of anti-drug Abs at week 4	24 months	Yes

External Links

•   Altor Bioscience Corporation, Miramar, Florida, US
•   H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, US
•   MD Anderson Cancer Center Orlando